Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats

被引:90
作者
Lobenberg, R
Araujo, L
von Briesen, H
Rodgers, E
Kreuter, J
机构
[1] Univ Frankfurt, Inst Pharmaceut Technol, D-60439 Frankfurt, Germany
[2] Chemotherapeut Res Inst, D-60596 Frankfurt, Germany
[3] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland
关键词
nanoparticles; drug targeting; macrophages; AZT; AIDS;
D O I
10.1016/S0168-3659(97)00105-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Cells of the reticuloendothelial system (RES e.g. macrophages) play an important role in the immunopathogenesis of AIDS. The objective of the present study was to investigate the possibility of specifically targeting antiviral drugs such as azidothymidine (AZT) to macrophages using nanoparticles as colloidal drug carriers. In a first series of experiments the body distribution of C-14-labelled AZT bound to nanoparticles and a similarly prepared control solution with unbound AZT were studied in rats after intravenous injection. In a second series of experiments polysorbate 80-coated nanoparticles and a solution of AZT in saline were tested. C-14-labelled AZT was bound to nanoparticles using the surfactant bis(2-ethylhexyl) sulphosuccinate sodium (DOSS). The radioactivity in several organs, including those containing large numbers of macrophages, was measured after intravenous injection of the AZT-nanoparticles and the AZT-control solutions. AZT concentrations were up to 18 times higher in organs belonging to the RES if the drug was bound to nanoparticles compared with unbound AZT. These results demonstrate that nanoparticles are a potential drug targeting system for anti-AIDS drugs. The increase in drug concentration at the sites containing abundant macrophages may allow a reduction in dosage to reduce systemic toxicity. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:21 / 30
页数:10
相关论文
共 39 条
[1]  
ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44
[2]   Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles [J].
Alyautdin, RN ;
Petrov, VE ;
Langer, K ;
Berthold, A ;
Kharkevich, DA ;
Kreuter, J .
PHARMACEUTICAL RESEARCH, 1997, 14 (03) :325-328
[3]   AIDS research - HIV's other immune-system targets: Macrophages [J].
Balter, M .
SCIENCE, 1996, 274 (5292) :1464-1465
[4]   Azidothymidine homodinucleotide-loaded erythrocytes as bioreactors for slow delivery of the antiretroviral drug azidothymidine [J].
Benatti, U ;
Giovine, M ;
Damonte, G ;
Gasparini, A ;
Scarfi, S ;
DeFlora, A ;
Fraternale, A ;
Rossi, L ;
Magnani, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 220 (01) :20-25
[5]   INHIBITION OF HIV IN-VITRO BY ANTIVIRAL DRUG-TARGETING USING NANOPARTICLES [J].
BENDER, A ;
SCHAFER, V ;
STEFFAN, AM ;
ROYER, C ;
KREUTER, J ;
RUBSAMENWAIGMANN, H ;
VONBRIESEN, H .
RESEARCH IN VIROLOGY, 1994, 145 (3-4) :215-220
[6]   Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro [J].
Bender, AR ;
vonBriesen, H ;
Kreuter, J ;
Duncan, IB ;
RubsamenWaigmann, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1467-1471
[7]   UPTAKE OF SURFACTANT-COATED POLY(METHYL METHACRYLATE)-NANOPARTICLES BY BOVINE BRAIN MICROVESSEL ENDOTHELIAL-CELL MONOLAYERS [J].
BORCHARD, G ;
AUDUS, KL ;
SHI, FL ;
KREUTER, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 110 (01) :29-35
[8]  
BORCHARD G, 1993, UNTERSUCHUNG INTERAK
[9]   TISSUE DISTRIBUTION OF ANTI-TUMOR DRUGS ASSOCIATED WITH POLYALKYLCYANOACRYLATE NANOPARTICLES [J].
COUVREUR, P ;
KANTE, B ;
LENAERTS, V ;
SCAILTEUR, V ;
ROLAND, M ;
SPEISER, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (02) :199-202
[10]   PARTICLE-SIZE AND SIZE DISTRIBUTION OF POLY(BUTYL-2-CYANOACRYLATE) NANOPARTICLES .1. INFLUENCE OF PHYSICOCHEMICAL FACTORS [J].
DOUGLAS, SJ ;
ILLUM, L ;
DAVIS, SS ;
KREUTER, J .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 1984, 101 (01) :149-158